Schedule 13D ownership disclosure
CRISPR Therapeutics AG
Security class unavailable · CUSIP: H17182108
Event date: 2018-12-26
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 5,380,940
- Percent of class
- 10.4000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001341004-18-000692
- Form type
- SC 13D
- Filer
- CRISPR Therapeutics AG
- CIK
- CIK 1674416
- Filed
- Dec 28, 2018
- Reporting period
- Dec 26, 2018
- Description
- Schedule 13D beneficial ownership